Abstract
This study aims to elucidate the mechanism by which Xihuang Pill induces pyroptosis in glioma cells via the regulation of miR-21-5p. Human glioma cell lines U-87 and LN-229 were used as experimental models to assess the effects of Xihuang Pill on glioma pyroptosis. Cells were incubated with Xihuang Pill extract at concentrations of 7.5, 15, and 30µg/mL for 24h, alongside transfection with miR-21-5p mimic, an overexpression vector for STAT3, or incubation with 50µg/mL of the STAT3 activator Colivelin for 4h. Cell viability was measured using the CCK-8 assay, apoptosis was detected by flow cytometry, and expression levels of p-STAT3/STAT3 and pyroptosis-related proteins were determined by Western Blot. Additionally, cleaved caspase-1 was assessed by immunofluorescence, miR-21-5p expression by qRT-PCR, and STAT3 binding to the miR-21-5p promoter region by ChIP and dual-luciferase reporter assays. Results showed that Xihuang Pill significantly reduced cell viability, increased apoptosis, and upregulated the expression of pyroptosis-related proteins such as NLRP3, IL-1β, cleaved caspase-1, and GSDMD-N, while reducing p-STAT3/STAT3 and miR-21-5p levels (P < 0.05). Xihuang Pill inhibited STAT3 activation, which modulated miR-21-5p expression by binding to its promoter region. Co-transfection with miR-21-5p mimic reversed the effect of Xihuang Pill on glioma pyroptosis (P < 0.05). In conclusion, Xihuang Pill promotes glioma cell pyroptosis through the STAT3/miR-21-5p pathway.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.